Skip links and keyboard navigation

Heart failure medications

Heart failure medication titration plan

The Heart Failure Medication Titration Plan (PDF, 1.39MB) is endorsed by the Queensland Statewide Heart Failure Service Steering Committee and is approved by Clinical Information Management for compliance with form standards for Queensland Health. Problem solving guidelines are on the back of the form.

Instructions on use of form

The Heart Failure Medication Titration Plan can improve up-titration of medications in heart failure1. Users of the form are encouraged to file the original in the medical notes and send a copy to the GP. If the GP is not managing the titration, the form is still useful as it gives the GP concise symptom management problem-solving guidelines and a variable diuretic plan.

NB: the form is endorsed for titration by GPs, Heart Failure Nurse Practitioners or Heart Failure Nurse Practitioner candidates.

1 Hickey A, Suna J, Marquart L et al. Improving medication titration in heart failure by embedding a structured medication titration plan. Int J Cardiol 2016;224:99-106.

Sacubitril/valsartan (Entresto) Fact Sheet

Sacubitril/valsartan (Entresto) is a new drug class called angiotensin receptor-neprilysin inhibitor (ARNI). The Pharmaceutical Benefits Scheme (PBS) recommends Entresto for patients with Heart Failure who are symptomatic with NYHA class II-IV. For prescribing information see the Entresto Fact Sheet (PDF, 278KB). ARNI is included on the revised Heart Failure Medication Titration Plan.

Last updated: 26 July 2019